Cost-Effectiveness of Sibutramine in the Treatment of Obesity

Medical Decision Making

Volumn 24, Issue 1, 2004, Pages 9-19

  Warren, Emma ^a,b   Brennan, Alan ^a   Akehurst, Ron ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Operational Research   (United Kingdom)

Author keywords

Cost utility; Model; Obesity; Sibutramine

Indexed keywords

PLACEBO; SIBUTRAMINE;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL PATHWAY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIET; DISEASE MODEL; DRUG EFFICACY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; QUALITY OF LIFE; RISK ASSESSMENT; WEIGHT REDUCTION;

ADULT; AGED; APPETITE DEPRESSANTS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; COUNSELING; CYCLOBUTANES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG COSTS; FEMALE; GREAT BRITAIN; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 1642443523     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X03261565     Document Type: Article

References (32)

1. Department of Health. Health Survey for England 1998, Cardiovascular Disease. Available from: http://www.official-documents. co.uk/document/doh/survey98/hse98.htm.
2. West R. Obesity. London: London Office for Health Economics; 1994.
3. Chan JM, Stamper MJ, Rimm EB, Willett WC, Colditz GA. Obesity fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17(9):961-9.
4. Colditz GA, Walter MBBS, Willcott C, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122(7):481-6.
5. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol. 1995; 141(12):1128-41.
6. Smith IG, Goulder MA. Randomised placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001;50(6):505-12.
7. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356:2119-25.
8. SmPC. Reductil, summary of product characteristics. Available from: www.emea.eu.int/index.htm.
9. Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomised trials of sibutramine versus placebo. Am J Managed Care. 2001;7(9):875-83.
10. Heitman BL, Garby L. Patterns of long-term weight changes in overweight developing Danish man and women aged between 30 and 60 Years. Int J Obes. 1999;23:1074-8.
11. British National Formulary. British National Formulary 43; 2002. Available from: www.bnf.org.uk.
12. Netten A, Dennett J. Unit Costs of Health and Social Care 1998. Canterbury (UK): Personal Social Services Research Unit, University of Kent; 1998.
13. Department of Health. Financial Matters, Appendix 1, Health Service Cost Index. London: Department of Health; 2000.
14. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Am Heart Anderson Med/Sci Statement. 1991;83(1):356-63.
15. Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil HAW. Coronary event and case fatality rates in an English population: results of the Oxford Myocardial Infarction Incidence Study. Heart. 1998;80(1):40-44.
16. Government Actuary Department. England and Wales life tables. Available from: http://www.gad.gov.uk/.
17. Centers for Disease Control and Prevention. National Vital Statistics Report. United States Life Tables. Atlanta (GA): Centers for Disease Control and Prevention; 1998.
18. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736-41.
19. Kuntz KM, Tsevat J, Goldman L. Weinstein MC. Cost-effectiveness of routine coronary heart angiography after acute myocardial infarction. Circulation. 1996;94(5):957-65.
20. Pickin DM. Cost-effectiveness of MHG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart. 1999;82(3):325-32.
21. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81(9):1110-5.
22. Sjostrom D, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477-84.
23. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care. 1999;22(8):1266.
24. Resnick HE, Halter JB, Valsania P, Lin X. Differential effects of BMI on diabetes risk among black and white Americans. Diabetes Care. 1998;21(11):1828.
25. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years. Am J Epidemiol. 1999;146(6):491-503.
26. De Grauw WJC, Van Den Hoogen HJM, Van De Lisdonk EH, Van Gerwen WHEM, Van Weel C. Control group characteristics and study outcomes: empirical data from a study on mortality of patients with type 2 diabetes mellitus in Dutch general practice. J Epidemiol Community Health. 1998;52(Suppl 1):9s-12s.
27. Hughes D, McGuire A, Elliot H, et al. The cost of obesity in the United Kingdom. J Med Econ. 1999;2:143-53.
28. Brown JB, Nichols GA, Glauber HS, Bakst AW, Schaffer M, Kelleher CC. Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health-System Pharm. 2001;58(2):151-7.
29. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol. 1998;51(11):1115-29.
30. MAG Mutual Healthcare Solutions. Physicians Fee and Coding Guide. Duluth (GA); MAG Mutual Healthcare Solutions; 2000.
31. Laupacis A, Feeny D, Detsky A, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146(4):473-81.
32. Paeratakul S, Lovejoy JC, Ryan DH, Bray GA. The relation of gender, race and socioeconomic status to obesity and obesity comorbidities in a sample of US adults. Int J Obes. 2002;26:1205-10.